Few firms benefit from rewards under EU Paediatric Regulation
This article was originally published in Scrip
Only a few companies have benefited from incentives for developing medicines for children since the European Paediatric Regulation came into force three years ago, says the European Medicines Agency in its first mandatory report on the regulation.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.